{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:55:52Z","timestamp":1792958152515,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichische Akademie der Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032679","name":"St. Anna Children's Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xcrm.2025.102304","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:04:24Z","timestamp":1755749064000},"page":"102304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML"],"prefix":"10.1016","volume":"6","author":[{"given":"Ben","family":"Haladik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Maurer-Granofszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zoescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Jimenez-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Frohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Segarra-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kartnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rashkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Repiscak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Dworzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Boztug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102304_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102304_bib2","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995\u20132009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102304_bib4","article-title":"Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease","volume":"23","author":"Tierens","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xcrm.2025.102304_bib5","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102304_bib6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102304_bib7","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","article-title":"Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia","volume":"33","author":"McNeer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102304_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102304_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ccell.2023.10.008","article-title":"A longitudinal single-cell atlas of treatment response in pediatric AML","volume":"41","author":"Lambo","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102304_bib12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","article-title":"Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse","volume":"76","author":"Farrar","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102304_bib13","doi-asserted-by":"crossref","first-page":"56746","DOI":"10.18632\/oncotarget.10778","article-title":"Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing","volume":"7","author":"Masetti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102304_bib14","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2004-11-4544","article-title":"Pharmacogenetics of outcome in children with acute lymphoblastic leukemia","volume":"105","author":"Rocha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102304_bib16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.21.01422","article-title":"Polygenic Ara-C response score identifies pediatric patients with acute myeloid leukemia in need of chemotherapy augmentation","volume":"40","author":"Elsayed","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102304_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-015-1766-4","article-title":"Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy","volume":"101","author":"Amaki","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101197","article-title":"Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9\/SAMD9L syndromes","volume":"33","author":"Sahoo","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12185-017-2285-2","article-title":"Heterogeneity of GATA2-related myeloid neoplasms","volume":"106","author":"Hirabayashi","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib21","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/cancers13102336","article-title":"Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102304_bib22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib23","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to \u0394N flow cytometry: a Children\u2019s Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102304_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine-moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102304_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102304_bib27","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2025.102304_bib28","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102304_bib30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"Acanda De La Rocha","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102304_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2643-3230.BCD-22-0011","article-title":"Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine","volume":"3","author":"Wang","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102304_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246240","article-title":"Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML","volume":"14","author":"Strachan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102304_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100730","article-title":"Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome","volume":"53","author":"Cucchi","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.xcrm.2025.102304_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2022.282424","article-title":"Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia","volume":"109","author":"Maurer-Granofszky","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102304_bib35","article-title":"Mask R-CNN","author":"He","year":"2017","journal-title":"arXiv"},{"key":"10.1016\/j.xcrm.2025.102304_bib36","article-title":"Adversarial Autoencoders","author":"Makhzani","year":"2015","journal-title":"arXiv"},{"key":"10.1016\/j.xcrm.2025.102304_bib37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","article-title":"Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma","volume":"4","author":"Kropivsek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102304_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102304_bib39","article-title":"Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay","volume":"7","author":"Stieglitz","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102304_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102304_bib41","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/bloodadvances.2020001934","article-title":"Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms","volume":"4","author":"Spinner","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102304_bib42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102304_bib44","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","volume":"48","author":"Corces","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102304_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nmeth.4401","article-title":"chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data","volume":"14","author":"Schep","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102304_bib46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41577-018-0048-9","article-title":"Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis","volume":"18","author":"Zaiss","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102304_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102304_bib48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102304_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003267","article-title":"CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia","volume":"136","author":"Schmoellerl","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib51","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102304_bib52","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2017.08.007","article-title":"High-Definition Medicine","volume":"170","author":"Torkamani","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ccell.2022.07.009","article-title":"Precision medicine in AML: Function plus-omics is better than either alone","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102304_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000312","article-title":"Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia","volume":"4","author":"Schumich","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.xcrm.2025.102304_bib56","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102304_bib58","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102304_bib60","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1038\/s41467-022-33244-6","article-title":"Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102304_bib61","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1001\/jama.2010.1862","article-title":"Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia","volume":"304","author":"Gentles","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2025.102304_bib62","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41375-018-0227-5","article-title":"The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia","volume":"33","author":"Duployez","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102304_bib63","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102304_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-019-0775-1","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia","volume":"11","author":"Van Tilburg","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.xcrm.2025.102304_bib65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08880018.2020.1752869","article-title":"A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies","volume":"37","author":"Goldberg","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102304_bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ccell.2021.01.004","article-title":"The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support","volume":"39","author":"Irmisch","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102304_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111288","article-title":"SMNDC1 links chromatin remodeling and splicing to regulate pancreatic hormone expression","volume":"40","author":"Casteels","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102304_bib70","author":"Abdulla"},{"key":"10.1016\/j.xcrm.2025.102304_bib71","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41597-020-00608-w","article-title":"An annotated fluorescence image dataset for training nuclear segmentation methods","volume":"7","author":"Kromp","year":"2020","journal-title":"Sci. Data"},{"key":"10.1016\/j.xcrm.2025.102304_bib72","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1109\/TMI.2020.3015198","article-title":"AttentionBoost: Learning what to attend for gland segmentation in histopathological images by boosting fully convolutional networks","volume":"39","author":"Gunesli","year":"2020","journal-title":"IEEE Trans. Med. Imaging"},{"key":"10.1016\/j.xcrm.2025.102304_bib73","doi-asserted-by":"crossref","first-page":"e1008179","DOI":"10.1371\/journal.pcbi.1008179","article-title":"Detection and segmentation of morphologically complex eukaryotic cells in fluorescence microscopy images via feature pyramid fusion","volume":"16","author":"Korfhage","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.xcrm.2025.102304_bib74","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/s41592-019-0612-7","article-title":"Nucleus segmentation across imaging experiments: the 2018 Data Science Bowl","volume":"16","author":"Caicedo","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102304_bib69","series-title":"Ultimate ATAC-Seq Data Processing & Quantification Pipeline (v1.1.0)","author":"Reichl","year":"2024"},{"key":"10.1016\/j.xcrm.2025.102304_bib75","series-title":"Genomics in the cloud: using Docker, GATK, and","author":"Auwera","year":"2020"},{"key":"10.1016\/j.xcrm.2025.102304_bib76","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102304_bib77","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:23:33Z","timestamp":1772918613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666379125003775"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102304","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102304"}}